Pediatric Drugs

, Volume 19, Issue 4, pp 277–290 | Cite as

Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months

  • Victoria C. ZiesenitzEmail author
  • Andreas Zutter
  • Thomas O. Erb
  • Johannes N. van den Anker
Current Opinion


Ibuprofen is a non-steroidal anti-inflammatory drug frequently administered to children of various ages for relief of fever and pain and is approved as an over-the-counter medication in many countries worldwide. Although there are extensive data on its efficacy and safety in children and adults, there are divergent dosing recommendations for analgesia and treatment of fever in infants, especially in the age group between 3 and 6 months of age. In this article, we have assessed the safety and efficacy of ibuprofen use in infants in an attempt to find the optimal method of pain and fever management in this specific age group. Based on the current evidence, short-term use of ibuprofen is considered safe in infants older than 3 months of age having a body weight above 5–6 kg when special attention is given to the hydration of the patient. Ibuprofen should be prescribed based on body weight using a dose of 5–10 mg/kg. This dose can be administered 3–4 times a day resulting in a maximum total daily dose of 30–40 mg/kg. The rectal route has been shown to be less reliable because of erratic absorption, especially in young infants. Since most efficacy and safety data have been derived from trials in infants with fever, future studies should focus on the efficacy of ibuprofen in young infants with pain.


Ibuprofen Patent Ductus Arteriosus Young Infant Necrotizing Fasciitis Reporting Odds Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards

Conflict of interest

All authors (VCZ, AZ, TOE, JNvdA) declare that they have no conflict of interest.


This work was supported by National Institutes of Health grants from the Eunice Shriver National Institute of Child Health and Human Development (5T32HD087969 & 5U54HD090254) to John van den Anker.


  1. 1.
    Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.CrossRefPubMedGoogle Scholar
  2. 2.
    Morris JL, Rosen DA, Rosen KR. Nonsteroidal anti-inflammatory agents in neonates. Paediatr Drugs. 2003;5(6):385–405.CrossRefPubMedGoogle Scholar
  3. 3.
    Seyberth HW, Leonhardt A, Tonshoff B, Gordjani N. Prostanoids in paediatric kidney diseases. Pediatr Nephrol. 1991;5(5):639–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Aranda JV, Varvarigou A, Beharry K, Bansal R, Bardin C, Modanlou H, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997;86(3):289–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996;275(7):539–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed. 1997;76(3):F179–84.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    European Medicines Agency. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of the Regulation (EC) No 1901/2006, as amended—Ibuprofen—(DE/W/040/pdWS/001). 2014 April 4, 2014 December 23, 2016.Google Scholar
  8. 8.
    Fachinformation. PecFent® Nasenspray: Archimedes Pharma Germany GmbH; April 2011.Google Scholar
  9. 9.
    Reckitt Benckiser Deutschland GmbH. Fachinformation Nurofen Junior Fieber- und Schmerzsaft Erdbeer 40 mg/ml Suspension zum Einnehmen. 2015 January 2015 [cited 2016 December 21, 2016]; Available from:
  10. 10.
    Reckitt Benckiser Healthcare (UK) Ltd. Nurofen for Children Orange Baby/Nurofen for Children 3 months to 9 years. 2014 October 2, 2014 December 21, 2016. Available from:
  11. 11.
    Reckitt Benckiser Healthcare (UK) Ltd. Nurofen for Children Strawberry/Nurofen Strawberry 3 months to 12 years. 2014 October 2, 2014 December 21, 2016. Available from:
  12. 12.
    Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. The Cochrane database of systematic reviews. 2015;18(2):CD003481.Google Scholar
  13. 13.
    Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet. 1998;34(2):101–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Walson PD, Mortensen ME. Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children. Clin Pharmacokinet. 1989;17(Suppl 1):116–37.CrossRefPubMedGoogle Scholar
  15. 15.
    Leroy S, Mosca A, Landre-Peigne C, Cosson MA, Pons G. Ibuprofen in childhood: evidence-based review of efficacy and safety. Archives de pediatrie. 2007;14(5):477–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Halpern SM, Fitzpatrick R, Volans GN. Ibuprofen toxicity. A review of adverse reactions and overdose. Adverse drug reactions and toxicological reviews. 1993;12(2):107–28.Google Scholar
  17. 17.
    Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998;23(4):247–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Rey E, Pariente-Khayat A, Gouyet L, Vauzelle-Kervroedan F, Pons G, D’Athis P, et al. Stereoselective disposition of ibuprofen enantiomers in infants. Br J Clin Pharmacol. 1994;38(4):373–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Paediatr Drugs. 2001;3(11):817–58.CrossRefPubMedGoogle Scholar
  20. 20.
    Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther. 2002;72(1):62–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2005;59(1):62–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004;76(2):119–27.CrossRefPubMedGoogle Scholar
  23. 23.
    Deputy Division Director Review—NDA 22348 Supplement 005—Caldolor pediatric indication—Reference ID: 3849398. 2015 November 19, 2015 [cited 2017 January 11, 2017]. Available from:
  24. 24.
    Kyllonen M, Olkkola KT, Seppala T, Ryhanen P. Perioperative pharmacokinetics of ibuprofen enantiomers after rectal administration. Paediatr Anaesth. 2005;15(7):566–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr. 1992;121(6):969–73.CrossRefPubMedGoogle Scholar
  26. 26.
    Vilenchik R, Berkovitch M, Jossifoff A, Ben-Zvi Z, Kozer E. Oral versus rectal ibuprofen in healthy volunteers. J Popul Ther Clin Pharmacol Journal de la therapeutique des populations et de la pharamcologie clinique. 2012;19(2):e179–86.Google Scholar
  27. 27.
    Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17(6):275–342.CrossRefPubMedGoogle Scholar
  28. 28.
    Jacqz-Aigrain E, Anderson BJ. Pain control: non-steroidal anti-inflammatory agents. Semin Fetal Neonatal Med. 2006;11(4):251–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Ulinski T, Guigonis V, Dunan O, Bensman A. Acute renal failure after treatment with non-steroidal anti-inflammatory drugs. Eur J Pediatr. 2004;163(3):148–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Section on Clinical Pharmacology and Therapeutics, Committee on Drugs, Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics. 2011;127(3):580–7.CrossRefGoogle Scholar
  31. 31.
    Lesko SM, Mitchell AA. Renal function after short-term ibuprofen use in infants and children. Pediatrics. 1997;100(6):954–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Vifor Consumer Health SA. Fachinformation Algifor® Junior. 2012 August 2012 [cited 2016 December 21, 2016]. Available from:
  33. 33.
    Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101(7):1060–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17.CrossRefPubMedGoogle Scholar
  35. 35.
    Falup-Pecurariu O, Man SC, Neamtu ML, Chicin G, Baciu G, Pitic C, et al. Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial. Hum Vaccin Immunother. 2017;13(3):649–60.CrossRefPubMedGoogle Scholar
  36. 36.
    Clark E, Plint AC, Correll R, Gaboury I, Passi B. A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma. Pediatrics. 2007;119(3):460–7.CrossRefPubMedGoogle Scholar
  37. 37.
    McIntyre J, Hull D. Comparing efficacy and tolerability of ibuprofen and paracetamol in fever. Arch Dis Child. 1996;74(2):164–7.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Simila S, Kouvalainen K, Keinanen S. Oral antipyretic therapy. Scand J Rheumatol. 1976;5(2):81–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Wilson G, Guerra AJ, Santos NT. Comparative study of the antipyretic effect of ibuprofen (oral suspension) and paracetamol (suppositories) in paediatrics. J Int Med Res. 1984;12(4):250–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Wilson JT, Brown RD, Kearns GL, Eichler VF, Johnson VA, Bertrand KM, et al. Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr. 1991;119(5):803–11.CrossRefPubMedGoogle Scholar
  41. 41.
    Eccles R. Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. J Clin Pharm Ther. 2006;31(4):309–19.CrossRefPubMedGoogle Scholar
  42. 42.
    Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin. 2009;25(9):2207–22.CrossRefPubMedGoogle Scholar
  43. 43.
    Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44(3):489–506.CrossRefPubMedGoogle Scholar
  44. 44.
    Goldman RD, Ko K, Linett LJ, Scolnik D. Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. Ann Pharmacother. 2004;38(1):146–50.CrossRefPubMedGoogle Scholar
  45. 45.
    Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children’s pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004;158(6):521–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA. 1995;273(12):929–33.Google Scholar
  47. 47.
    Lesko SM, Mitchell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics. 1999;104(4):e39.CrossRefPubMedGoogle Scholar
  48. 48.
    Ashraf E, Ford L, Geetha R, Cooper S. Safety profile of ibuprofen suspension in young children. Inflammopharmacology. 1999;7(3):219–25.CrossRefPubMedGoogle Scholar
  49. 49.
    Yue Z, Jiang P, Sun H, Wu J. Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system. Eur J Clin Pharmacol. 2014;70(4):479–82.CrossRefPubMedGoogle Scholar
  50. 50.
    Bianciotto M, Chiappini E, Raffaldi I, Gabiano C, Tovo PA, Sollai S, et al. Drug use and upper gastrointestinal complications in children: a case-control study. Arch Dis Child. 2013;98(3):218–21.CrossRefPubMedGoogle Scholar
  51. 51.
    Kauffman RE, Lieh-Lai M. Ibuprofen and increased morbidity in children with asthma: fact or fiction? Paediatr Drugs. 2004;6(5):267–72.CrossRefPubMedGoogle Scholar
  52. 52.
    Goraya JS, Virdi VS. To the editor: exacerbation of asthma by ibuprofen in a very young child. Pediatr Pulmonol. 2001;32(3):262.CrossRefPubMedGoogle Scholar
  53. 53.
    Menendez R, Venzor J, Ortiz G. Failure of zafirlukast to prevent ibuprofen-induced anaphylaxis. Ann Allergy Asthma Immunol. 1998;80(3):225–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, Szefler SJ, et al. Acetaminophen versus ibuprofen in young children with mild persistent asthma. N Engl J Med. 2016;375(7):619–30.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Sheehan WJ, Phipatanakul W. Acetaminophen versus ibuprofen in mild persistent asthma. N Engl J Med. 2016;375(21):2099–100.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Uzoigwe CE, Ali OH. Acetaminophen versus ibuprofen in mild persistent asthma. N Engl J Med. 2016;375(21):2099.CrossRefPubMedGoogle Scholar
  57. 57.
    Kanabar D, Dale S, Rawat M. A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. Clin Ther. 2007;29(12):2716–23.CrossRefPubMedGoogle Scholar
  58. 58.
    Lesko SM, Louik C, Vezina RM, Mitchell AA. Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics. 2002;109(2):E20.CrossRefPubMedGoogle Scholar
  59. 59.
    Hadas D, Youngster I, Cohen A, Leibovitch E, Shavit I, Erez I, et al. Premarketing surveillance of ibuprofen suppositories in febrile children. Clin Pediatr. 2011;50(3):196–9.CrossRefGoogle Scholar
  60. 60.
    Romsing J, Walther-Larsen S. Peri-operative use of nonsteroidal anti-inflammatory drugs in children: analgesic efficacy and bleeding. Anaesthesia. 1997;52(7):673–83.CrossRefPubMedGoogle Scholar
  61. 61.
    Maunuksela EL, Ryhanen P, Janhunen L. Efficacy of rectal ibuprofen in controlling postoperative pain in children. Can J Anaesth. 1992;39(3):226–30.CrossRefPubMedGoogle Scholar
  62. 62.
    Kokki H, Hendolin H, Maunuksela EL, Vainio J, Nuutinen L. Ibuprofen in the treatment of postoperative pain in small children. A randomized double-blind-placebo controlled parallel group study. Acta Anaesthesiol Scand. 1994;38(5):467–72.CrossRefPubMedGoogle Scholar
  63. 63.
    Pfaff JA, Hsu K, Chennupati SK. The use of ibuprofen in posttonsillectomy analgesia and its effect on posttonsillectomy hemorrhage rate. Otolaryngol Head Neck Surg. 2016;155(3):508–13.CrossRefPubMedGoogle Scholar
  64. 64.
    Rainsford KD, Roberts SC, Brown S. Ibuprofen and paracetamol: relative safety in non-prescription dosages. J Pharm Pharmacol. 1997;49(4):345–76.CrossRefPubMedGoogle Scholar
  65. 65.
    Nahata MC, Durrell DE, Powell DA, Gupta N. Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol. 1991;40(4):427–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Kelley MT, Walson PD, Edge JH, Cox S, Mortensen ME. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clin Pharmacol Ther. 1992;52(2):181–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Brown RD, Wilson JT, Kearns GL, Eichler VF, Johnson VA, Bertrand KM. Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. J Clin Pharmacol. 1992;32(3):231–41.CrossRefPubMedGoogle Scholar
  68. 68.
    Har-Even R, Stepensky D, Britzi M, Soback S, Chaim AB, Brandriss N, et al. Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic-pharmacodynamic modeling analysis. J Clin Pharmacol. 2014;54(9):1023–30.CrossRefPubMedGoogle Scholar
  69. 69.
    Study Report for Study 573-CHC-9127-001 - Open Label Pharmacokinetic Study of a Single Dose Ibuprofen Suppository in Children with Fever. 2003 December 05, 2003 [cited 2017 January 11, 2017]. Available from:
  70. 70.
    Joshi YM, Sovani VB, Joshi VV, Navrange JR, Benakappa DG, Shivananda P, et al. Comparative evaluation of the antipyretic efficacy of ibuprofen and paracetamol. Indian Pediatr. 1990;27(8):803–6.PubMedGoogle Scholar
  71. 71.
    Sidler J, Frey B, Baerlocher K. A double-blind comparison of ibuprofen and paracetamol in juvenile pyrexia. Br J Clin Pract Suppl. 1990;70:22–5.PubMedGoogle Scholar
  72. 72.
    Díez-Domingo J, Planelles MV, Baldó JM, Ballester A, Núnez F, Jubert A, et al. Ibuprofen prophylaxis for adverse reactions to diphteria-tetanus-pertussis vaccination: a randomized trial. Curr Ther Res. 1998;59(8):579–88.CrossRefGoogle Scholar
  73. 73.
    Autret-Leca E, Gibb IA, Goulder MA. Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study. Curr Med Res Opin. 2007;23(9):2205–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Division of Paediatric Pharmacology and PharmacometricsUniversity of Basel Children’s HospitalBaselSwitzerland
  2. 2.Department of Paediatric CardiologyUniversity Children’s HospitalHeidelbergGermany
  3. 3.Division of Paediatric AnaesthesiologyUniversity of Basel Children’s HospitalBaselSwitzerland
  4. 4.Division of Clinical PharmacologyChildren’s National Health SystemWashington, DCUSA

Personalised recommendations